$CTDH News Article - Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
https://marketwirenews.com/news-releases/cycl...02757.html